ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag disease medicine clinical trials business cancer pharma

Biotech Buys Autoimmune Firm for $7B
Kerry Grens | Jul 16, 2015 | 1 min read
Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.
Infusion of Artificial Intelligence in Biology
Meenakshi Prabhune, PhD | Feb 23, 2024 | 10 min read
With deep learning methods revolutionizing life sciences, researchers bet on de novo proteins and cell mapping models to deliver customized precision medicines.
Roche Snags Tumor Tester for $1B
Kerry Grens | Jan 13, 2015 | 1 min read
The pharmaceutical company bought a majority stake in Foundation Medicine, a firm that develops personalized cancer-medicine diagnostics.
Artist's rendition of a yellow CAR T cell near a red cancer cell surrounded by red blood cells.
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free
Jef Akst | Feb 3, 2022 | 2 min read
First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.
Pharma Cooperates to Achieve Precision Medicine
Catherine Offord | Feb 1, 2017 | 7 min read
The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.
The Profits of Nonprofit
Megan Scudellari | Jan 1, 2011 | 7 min read
The surprising results when drug development and altruism collide
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
Who Benefits from Herceptin and Other Anti-HER2 Cancer Therapies?
Robert Fortner | Apr 12, 2020 | 7 min read
Calls to include a new breast cancer subtype in future clinical trials reveal fundamental disagreements about HER2’s role in the disease.
Human Clinical Trials Begin For Cervical Cancer Vaccines
Steve Bunk | Oct 26, 1997 | 6 min read
Efforts are under way to develop a vaccine against one of the world's deadliest illnesses, cervical cancer. Along with a number of university research laboratories, at least a half-dozen biotechnology and pharmaceutical companies are beginning clinical trials or are in preclinical development of such drugs. Efficacy in humans remains to be firmly established, but if the vaccines progress to later-phase trials, challenging jobs for immunologists, microbiologists, and biochemists will multiply. "
Breaking Barriers to Participation in Cancer Clinical Trials
Robert Finn | Feb 20, 2000 | 6 min read
This issue of The Scientist chronicles many promising areas of cancer research, comprising a wide range of approaches to the treatment and prevention of our second-leading cause of death. But before any of these disparate approaches can begin to affect the rate of cancer mortality, they must pass through the bottleneck of human clinical trials. The pace of new ideas through the clinical trial process can seem maddeningly slow to patients and researchers alike. It takes far too long to get safe

Run a Search

ADVERTISEMENT